Internet-based treatment of depressive symptoms in patients with tumors inside or outside of the central nervous system.
- Conditions
- brain tumorglioma100253221003871610029211
- Registration Number
- NL-OMON39265
- Lead Sponsor
- Vrije Universiteit Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 300
Experimental groups:;1: adult (>18 years of age) WHO Grade II low-grade glioma survivors.
Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account. ;2: adult (>18 years of age) WHO Grade III and Grade IV high-grade glioma patients with an estimated life expectancy of >3 months. Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account. ;Control groups:;1: adult (>18 years of age) WHO Grade II low-grade glioma survivors. Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account. ;2: adult (>18 years of age) WHO Grade III and Grade IV high-grade glioma patients with an estimated life expectancy of >3 months. Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account. ;3. adult (>18 years of age) patients with hematological malignancies without involvement of the central nervous system. Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account. ;4. adult (>18 years of age) patients with non-small cell lung cancer without clinical signs of central nervous system involvement. Mild to moderate depressive symptoms (CES-D score >=12). Participants have to have access to internet and an email account.
Suicidal intent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Measures are taken at 0 weeks (pre-test) and after conclusion of the<br /><br>intervention at 5 weeks (post-test), at 3 months follow-up and at 6 and 12<br /><br>months follow-up for high-grade glioma patients and at 12 months follow-up for<br /><br>low-grade glioma patients. The primary outcome measure is the change in<br /><br>depressive symptoms as measured by the Center for Epidemiological Studies<br /><br>Depression Scale (CES-D). This is a valid and reliable self-report<br /><br>questionnaire used to measure depressive feelings during the past week. The<br /><br>questionnaire consists of 20 propositions, where the respondent indicates how<br /><br>often this proposition applies to him/her (rarely or never, sometimes,<br /><br>regularly, most of the time or always). The sum score lies between 0 and 60. A<br /><br>higher score indicates more feelings of depression. In the general population,<br /><br>people with a score higher than 16 are considered depressed. </p><br>
- Secondary Outcome Measures
Name Time Method